Paper Details

  1. Home
  2. Paper Details

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.

Author: BerensonJames R, CampbellRichard A, ChenHaiming, LiZhi-Wei, SanchezEric, ShalitinDror, SteinbergJeffrey

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Vorinostat enhanced the anti-MM effects of melphalan and bortezomib in vitro and in vivo. It showed significant inhibition of tumor growth when combined with melphalan in vivo.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: Examine the antitumor activity of the histone deacetylase inhibitor vorinostat's antitumor activity against multiple myeloma (MM) using cell lines and a murine xenograft model. METHODS: RPMI8226, U266, and MM1S cells were cultured for 48 h in the presence of media, vorinostat, melphalan...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1600-0609.2009.01384.x

データ提供：米国国立医学図書館（NLM）

Vorinostat: A Potential Weapon in the Fight Against Multiple Myeloma

Myeloma, a type of blood cancer, is a formidable foe, like a relentless desert wind. This research investigates the potential of Vorinostat, a histone deacetylase inhibitor, as a potent weapon against multiple myeloma. The researchers, like skilled warriors, employed a combination of in vitro and in vivo experiments to assess the antitumor activity of Vorinostat.

Synergy in the Desert of Cancer Research

Vorinostat, like a desert oasis, exhibits synergistic effects when combined with existing chemotherapy agents. The study reveals that Vorinostat significantly enhances the anti-myeloma effects of both melphalan and bortezomib, leading to a more potent attack against cancer cells. This synergy, like a sudden burst of wind, could lead to improved treatment outcomes for patients battling this disease.

Hope for a Brighter Future

The results of this research, like a shimmering mirage, offer hope for a brighter future for myeloma patients. The potential of Vorinostat, in combination with existing therapies, suggests a new path towards effective treatment and improved survival. This research serves as a beacon of hope, guiding the way towards better therapies for those facing this formidable disease.

Dr. Camel's Conclusion

This research highlights the promising potential of Vorinostat as a new weapon in the fight against multiple myeloma. Its synergistic effect with other therapies could significantly improve treatment outcomes and offer a glimmer of hope for patients facing this daunting disease. This research provides a compelling argument for further investigation of Vorinostat as a potential treatment option for multiple myeloma.
Date :
  1. Date Completed 2010-03-26
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

19929977

DOI: Digital Object Identifier

10.1111/j.1600-0609.2009.01384.x

Related Literature

Article Analysis
・Effects of melphalan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.